Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin alone versus empagliflozin + finerenone for albuminuria in chronic kidney disease
TCTR20260821002Phase 3Not yet recruiting
- Sponsor
- N/A
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin, finerenone in chronic kidney disease (CKD), sponsored by N/A. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
empagliflozinfinerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on TCTR20260821002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260821002.